Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors Shira DorotJames TankelAlberto Gabizon Original Article 08 July 2022 Pages: 109 - 114
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients Hirotsugu KenmotsuChiyo K. ImamuraYusuke Tanigawara Original Article 12 July 2022 Pages: 115 - 123
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg Yi-Han ChienGudrun WürthweinGeorg Hempel Original Article Open access 14 July 2022 Pages: 125 - 136
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship Kazuhiko NakagawaEdward B. GaronMartin Reck Original Article Open access 16 July 2022 Pages: 137 - 148
Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer Fabrice BarlesiLaure DeymeDominique Barbolosi Original Article 22 July 2022 Pages: 149 - 160
Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128 Emily J. KoubekRachel A. KudgusJoel M. Reid Original Article 27 July 2022 Pages: 161 - 174
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies Patrick M. BolandChristos FountzilasAntonio Jimeno Original Article 29 July 2022 Pages: 175 - 187
Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study Loek A. W. de JongFortuné M. K. ElekonawoNielka P. van Erp Correction Open access 22 June 2022 Pages: 189 - 190